Voloridge Investment Management
REGN icon

Voloridge Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Voloridge Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
+15,364
New +$11.8M 0.05% 462
2025
Q4 		– Sell
-172,836
Closed -$97.2M – 1325
2025
Q3 		$97.2M Sell
172,836
-107,024
-38% -$60.5M 0.33% 71
2025
Q2 		$147M Buy
279,860
+51,590
+23% +$28.8M 0.54% 25
2025
Q1 		$145M Buy
228,270
+16,142
+8% +$11.1M 0.54% 20
2024
Q4 		$151M Buy
+212,128
New +$178M 0.53% 26
2024
Q1 		– Sell
-33,209
Closed -$29.2M – 1317
2023
Q4 		$29.2M Buy
33,209
+600
+2% +$494K 0.11% 232
2023
Q3 		$26.8M Buy
32,609
+14,301
+78% +$11.2M 0.13% 216
2023
Q2 		$13.2M Buy
18,308
+5,464
+43% +$4.21M 0.06% 391
2023
Q1 		$10.6M Buy
12,844
+6,830
+114% +$5.15M 0.05% 440
2022
Q4 		$4.34M Buy
+6,014
New +$4.44M 0.02% 693
2022
Q1 		– Sell
-2,588
Closed -$1.63M – 1654
2021
Q4 		$1.63M Sell
2,588
-21,705
-89% -$13.3M 0.01% 1136
2021
Q3 		$14.7M Buy
24,293
+22,346
+1,148% +$13.9M 0.09% 295
2021
Q2 		$1.09M Buy
+1,947
New +$986K 0.01% 1221
2021
Q1 		– Sell
-43,195
Closed -$20.9M – 1616
2020
Q4 		$20.9M Sell
43,195
-103,466
-71% -$55.9M 0.18% 133
2020
Q3 		$82.1M Buy
146,661
+65,295
+80% +$39.6M 0.68% 19
2020
Q2 		$50.7M Buy
81,366
+72,124
+780% +$40.9M 0.58% 29
2020
Q1 		$4.51M Buy
+9,242
New +$3.81M 0.13% 178
2019
Q2 		– Sell
-8,988
Closed -$3.69M – 1013
2019
Q1 		$3.69M Buy
+8,988
New +$3.7M 0.11% 183
2018
Q3 		– Sell
-57,880
Closed -$20M – 438
2018
Q2 		$20M Buy
+57,880
New +$18.1M 0.54% 42
2018
Q1 		– Sell
-169,460
Closed -$63.7M – 625
2017
Q4 		$63.7M Buy
+169,460
New +$68.6M 1.39% 12
2017
Q3 		– Sell
-72,341
Closed -$35.5M – 510
2017
Q2 		$35.5M Buy
+72,341
New +$31.7M 0.88% 25
2016
Q2 		– Sell
-59,746
Closed -$21.5M – 383
2016
Q1 		$21.5M Buy
+59,746
New +$24.6M 0.5% 41
2015
Q2 		– Sell
-106,231
Closed -$48M – 373
2015
Q1 		$48M Buy
+106,231
New +$45M 2.32% 7

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Voloridge Investment Management's REGN Position: Q1 2026 in Review

Voloridge Investment Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 15,364 shares worth $11.9M. The stake represents 0.05% of the portfolio and ranks #462 among its holdings. This is a return to the name: Voloridge Investment Management previously reported a position in REGN as recently as Q3 2025.

Voloridge Investment Management first reported a position in REGN in Q1 2015 and has held it in 23 quarters since. The position peaked at $151M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Voloridge Investment Management held 15,364 shares of Regeneron Pharmaceuticals worth $11.9M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Voloridge Investment Management position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.05% of Voloridge Investment Management's portfolio in Q1 2026, its #462 holding.
  • Voloridge Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 23 quarters since.
  • Voloridge Investment Management's Regeneron Pharmaceuticals position peaked at $151M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.